Kemin Industries has signed an exclusive agreement with Pacific GeneTech (PGT) to develop and commercialize a broad-spectrum Salmonella vaccine.

The platform for the vaccine was developed by the University of Arkansas in collaboration with other U.S. and Canadian universities and with support from USDA.

Dr. Chris Nelson, President and CEO of Kemin, noted “Partnering with PGT on this vaccine will allow Kemin to deliver the technology to address Salmonella contamination in poultry.”  He added, “We are thrilled that we will be able to bring this vaccine to market around the world, to make the vaccine more accessible, and help reduce the prevalence rate of Salmonella in consumer poultry products.”

Kemin will develop the Salmonella vaccine and register it in the U.S. and the EU before extending availability to Southeast Asia.